Covaxin, India’s first COVID-19 vaccine, has demonstrated an interim clinical efficacy of 81% in the phase 3 clinical trial, vaccine maker Bharat Biotech said on Wednesday.
The vaccine demonstrated high clinical efficacy and significant immunogenicity against variants, the company’s CMD, Krishna Ella, said.
Explained: As you take the Covid-19 vaccine, some do’s and don’ts
Get vaccinated 24×7 now; Covaxin 81% effective: Key updates on Covid vaccines
Covid vaccine: Get a dose 24×7 at your convenience, says Health Minister Harsh Vardhan
Coronavirus | Vaccine can be taken 24/7, says Centre
Coronavirus | Covaxin efficacy is 81%, works against variants
Bharat Biotech says Covid-19 vaccine shows 81% interim efficacy
People should now be offered a choice of COVID-19 vaccine, feel experts
You can get covid vaccine 24×7 now
Govt allows 24×7 vaccination; Covaxin shows 81% interim efficacy | 10 points on Covid vaccines
Covid-19 vaccine: Covaxin shows interim clinical efficacy of 81% in phase-3 results, says Bharat Biotech